全文获取类型
收费全文 | 3056篇 |
免费 | 258篇 |
国内免费 | 21篇 |
专业分类
耳鼻咽喉 | 41篇 |
儿科学 | 144篇 |
妇产科学 | 57篇 |
基础医学 | 350篇 |
口腔科学 | 62篇 |
临床医学 | 211篇 |
内科学 | 537篇 |
皮肤病学 | 95篇 |
神经病学 | 294篇 |
特种医学 | 200篇 |
外科学 | 427篇 |
综合类 | 174篇 |
一般理论 | 1篇 |
预防医学 | 173篇 |
眼科学 | 72篇 |
药学 | 236篇 |
中国医学 | 47篇 |
肿瘤学 | 214篇 |
出版年
2023年 | 22篇 |
2022年 | 58篇 |
2021年 | 80篇 |
2020年 | 67篇 |
2019年 | 62篇 |
2018年 | 87篇 |
2017年 | 56篇 |
2016年 | 52篇 |
2015年 | 75篇 |
2014年 | 102篇 |
2013年 | 120篇 |
2012年 | 168篇 |
2011年 | 183篇 |
2010年 | 137篇 |
2009年 | 110篇 |
2008年 | 148篇 |
2007年 | 159篇 |
2006年 | 162篇 |
2005年 | 111篇 |
2004年 | 108篇 |
2003年 | 98篇 |
2002年 | 80篇 |
2001年 | 72篇 |
2000年 | 68篇 |
1999年 | 55篇 |
1998年 | 59篇 |
1997年 | 70篇 |
1996年 | 64篇 |
1995年 | 55篇 |
1994年 | 43篇 |
1993年 | 39篇 |
1992年 | 37篇 |
1991年 | 52篇 |
1990年 | 50篇 |
1989年 | 53篇 |
1988年 | 47篇 |
1987年 | 45篇 |
1986年 | 37篇 |
1985年 | 26篇 |
1984年 | 28篇 |
1983年 | 11篇 |
1982年 | 14篇 |
1981年 | 17篇 |
1980年 | 20篇 |
1979年 | 11篇 |
1978年 | 10篇 |
1977年 | 17篇 |
1976年 | 13篇 |
1975年 | 10篇 |
1970年 | 8篇 |
排序方式: 共有3335条查询结果,搜索用时 15 毫秒
101.
甲状腺术后瘢痕组织是甲状腺局部分切除术后由于手术方式及缝线填充而形成的组织,甲状腺术后瘢痕组织形成及其发生发展过程同一般的组织损伤修复病理过程一样,为渐进老化阶段的结缔组织,其内小血管稀少,胶原纤维增多[1]。由于甲状腺术后瘢痕组织其质地较硬,活动性差,超声声像图上表现缺乏典型特征,与癌灶极其相似,因此鉴别较困难。本文将介绍超声对于甲状腺术后的随诊应用,分析甲状腺术后瘢痕组织的超声检查特点并着重介绍超声动态观察甲状腺术后瘢痕组织的应用及其发展前景。 相似文献
102.
103.
104.
105.
106.
TM Husain DE Garrido A Aziz-Sultan JC Tang CJ Salgado 《The Journal of craniofacial surgery》2012,23(5):e380-e384
ABSTRACT: Arterial venous malformations (AVMs) are rare conditions that are difficult to manage. Therapeutic options include selective embolization with or without surgical excision. Recurrence, however, is high despite correction of the primary abnormality. Cosmetic concern is among the indications for treatment, particularly if the AVM occurs on the face or scalp. Historically, AVM excision and the residual defect correction have been performed separately. We present the first case reported of a successful embolization and interval excision with immediate reconstruction using a dermal fat graft, as a novel approach to correct soft tissue defect following the resection of an AVM.A 35-year-old man presented with a 20-year history of a nonpulsating mass posterior to the hairline in the right frontoparietal region, measuring 4.0 cm on its longest axis. Embolization of the AVM was achieved by injecting N-butyl cyanoacrylic acid and ethiodol. One month after embolization, surgical excision of the mass was performed. The resulting disfiguring contour defect was immediately corrected using a dermal fat graft harvested from the groin. At 4 months' follow-up, the graft was viable with no evidence of resorption or epidermal cyst formation. In addition, there was no recurrence of the AVM and no complications at the donor site.This case demonstrates the utility of a dermal fat grafts in correcting the impending defect in 1 stage avoiding a second-stage procedure and significant period of cosmetic disfigurement. This method should be considered as a treatment option for patients requiring moderately sized AVM excisions in cosmetically sensitive areas. 相似文献
107.
P Karagianni SA Polyzos N Kartali I Zografou C Sambanis 《Advances in medical sciences》2013,58(1):38-43
PurposeComparative efficacy of exenatide versus insulin glargine primarily on glucemic control, and secondarily on body mass index (BMI), lipid profile and blood pressure, in type 2 diabetes mellitus (T2DM) patients suboptimally treated with metformin monotherapy.Material/MethodsForty-seven inadequately treated T2DM patients on metformin assigned to exenatide (n=18) or insulin glargine (n=29) for 26 weeks. Glycosylated hemoglobin (HbA1c), serum lipids, BMI, systolic and diastolic blood pressure, and adverse events, including episodes of hypoglycemia and gastrointestinal symptoms, were recorded.ResultsEither treatment had a similar favorable mean reduction in HbA1c. However, more patients in exenatide group achieved HbA1c ≤ 7% at the 26th week compared with insulin glargine group (p=0.036). Insulin glargine group had significantly more episodes of hypoglycemia compared with exenatide group (p=0.039). Gastrointestinal adverse events were non-significantly higher in the exenatide group. A significantly greater BMI reduction was observed in exenatide group, whereas BMI was not altered in insulin glargine group. Total and LDL cholesterol (p=0.012), and triglycerides (p=0.016) significantly decreased, whereas HDL cholesterol increased (p=0.021) in the exenatide group, whereas only total cholesterol decreased in insulin glargine group. Changes in systolic and diastolic blood pressure were insignificant in both groups.ConclusionsExenatide provided similar reduction in HbA1c, but fewer episodes of hypoglycemia, compared with insulin glargine. Exenatide had also a favorable effect on weight loss, although more gastrointestinal adverse events. Exenatide may provide a justified alternative in second line treatment of T2DM, but more trials are required to elucidate its long-term safety and cost-effectiveness. 相似文献
108.
109.
目的 观察Ⅱ型胶原在T-2毒素诱导大鼠关节软骨早期损伤中的干预作用,在分子水平上寻找软骨损伤及修复的分子学生物标志,为探讨关节软骨损伤疾病的防治措施提供理论依据.方法 Wistar大鼠80只,按体质量随机分为4组:阴性对照组、阳性对照组、高剂量干预组、低剂量干预组,每组20只.阴性对照组食用常规成品颗粒饲料,其他3组食用含100 ng/kg T-2毒素染毒饲料;阴性对照组和阳性对照组饮自来水;低、高剂量干预组饮用含Ⅱ型胶原0.5、5.0 g/L的自来水.在3、5个月时处死大鼠,光镜下观察大鼠透明软骨的组织病理学改变,用酶联免疫吸附试验(ELISA法)检测大鼠血清Ⅱ型胶原羧基末端肽(CTX-Ⅱ)、软骨寡聚基质蛋白(COMP)及尿中吡啶啉(DPD)含量.结果 光镜下阳性对照组大鼠关节软骨细胞排列紊乱,软骨细胞变形、变性,可见大面积的软骨细胞坏死,而高、低剂量干预组表现为软骨表面原纤维形成,表层软骨细胞肿胀变圆,扁平的软骨细胞减少,软骨细胞簇集等骨关节炎早期病理改变.在3、5个月时,阴性对照组、阳性对照组、高剂量干预组、低剂量干预组大鼠血清CTX-Ⅱ含量分别为(18.77±4.61)、(25.07±9.17),(24.43±5.23)、(39.17±10.49),(21.11±5.02),(33.20±9.74),(19.87±4.53)、(29.73±9.32)μg/L;血清COMP含量分别为(5.43±2.75)、(6.38±2.23),(21.37±4.72)、(24.52±4.26),(17.27±4.77)、(20.32±4.74),(20.13±5.07)、(19.44±4.92)μg/L.其中,3个月时,与阴性对照组比较,阳性对照组血清CTX-Ⅱ含量明显升高(P<0.05),而低、高剂量干预组未见明显改变(P均> 0.05);5个月时,与阴性对照组比较,其他3组血清CTX-Ⅱ含量明显升高(P均< 0.05),而高、低剂量干预组明显低于阳性对照组(P均<0.05).3个月时,与阴性对照组比较,其他3组血清COMP含量明显升高(P均<0.05),而与阳性对照组比较,高剂量干预组血清COMP含量明显降低(P<0.05);5个月时,与阴性对照组比较,其他3组血清COMP含量明显升高(P均<0.05),而与阳性对照组比较,高、低剂量干预组血清COMP含量明显降低(P均<0.05).3、5个月时,上述4组大鼠尿液DPD含量分别为( 3.47±2.20)、(4.14±1.06),(4.09±2.48)、(4.33±3.43),(3.86±2.31)、(5.72±3.89),(3.58±2.77)、(4.23±2.90)μg/L,组间比较,差异无统计学意义(F值分别为2.608、2.436,P均>0.05).结论 Ⅱ型胶原能拮抗T-2毒素的软骨损伤作用,延缓关节软骨的破坏进程,降低大鼠血清中CTX-Ⅱ及COMP水平. 相似文献